Mechanism of Action
ZINPLAVA is the first and only FDA-approved human monoclonal antibody to reduce CDI recurrence, in patients aged ≥18 years receiving antibacterial drug treatment of CDI who are at high risk for CDI recurrence.
ZINPLAVA™
(bezlotoxumab) injection 25 mg/mL
Mechanism of Action
ZINPLAVA is the first and only FDA-approved human monoclonal antibody to reduce CDI recurrence, in patients aged ≥18 years receiving antibacterial drug treatment of CDI who are at high risk for CDI recurrence.
Adapted from Zhang Z et al. Infect Immun. 2015;83(1):405–416.
CDI = Clostridium difficile infection
1. Zhang Z, Chen X, Hernandez LD, et al. Toxin-mediated paracellular transport of antitoxin antibodies facilitates protection against Clostridium difficile infection. Infect Immun. 2015;83(1):405–416. doi:10.1128/IAI.02550-14
2. Wilcox MH, Gerding DN, Poxton IR, et al. Bezlotoxumab for prevention of recurrent Clostridium difficile infection. N Engl J Med. 2017;376(4):305–317. doi:10.1056/NEJMoa1602615
ZINPLAVA is a human monoclonal antibody that binds to Clostridium difficile toxin B indicated to reduce recurrence of Clostridium difficile infection (CDI) in patients 18 years of age or older who are receiving antibacterial drug treatment of CDI and are at high risk for CDI recurrence.
ZINPLAVA is not indicated for the treatment of CDI. ZINPLAVA is not an antibacterial drug. ZINPLAVA should only be used in conjunction with antibacterial drug treatment of CDI.
Before prescribing ZINPLAVATM (bezlotoxumab), please read the Prescribing Information. The Patient Information also is available.